Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Articles

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

Consumers and Providers Face Biosimilar Knowledge Hurdles

Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for patients with inflammatory bowel disease (IBD).

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

Cameron Santoro is an associate editor for The Center for Biosimilars

Videos

Here are the top 5 biosimilar articles for the week of June 30, 2025.

The Top 5 Biosimilar Articles for the Week of June 30

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

About

Editorial

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

The Center for Biosimilars - Biosimilars, Health Economics & Insights

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

This new eBook from The Center for Biosimilars

® tells the compelling story of how biosimilar development and uptake have been affected by COVID-19. Read it and find out how biosimilars may emerge from the pandemic as a more powerful, more valuable force in lower-cost medicine.

The Disruptor: How Coronavirus Disease 2019 (COVID-19) Has Affected the Development and Uptake of Biosimilars

Are you ready for the upcoming 2020 transition of insulins and other therapeutic proteins to US regulation as biologics and biosimilars? Find out what you need to know about the regulatory change with a new ebook from The Center for Biosimilars®.

Preparing for the 2020 Regulatory Transition of Insulin and Other Therapeutic Proteins

Strategies for Successful Adoption of Biosimilars in Practice: Takeaways From the West Cancer Center Experience

Biosimilars 101:  Practice Concerns, Market Acceptance, and the Biosimilars Pipeline

Pfizer Global Biosimilars Commercial Lead, Roman Irsiegler, gives his thoughts on why a sustainable biosimilars market is critical for the healthcare industry, and what stakeholders can do to achieve it.

How can we achieve a long-term sustainable biosimilars market?

What is key to achieving a long-term sustainable biosimilars market?

Resources

Strategies for Successful Adoption of Biosimilars in Practice: Takeaways From the West Cancer Center Experience

Date:

Biosimilars 101: Practice Concerns, Market Acceptance, and the Biosimilars Pipeline

Date:

How can we achieve a long-term sustainable biosimilars market?

Date:

What is key to achieving a long-term sustainable biosimilars market?

Date: